Natixis Advisors LLC acquired a new stake in shares of Haemonetics Co. (NYSE:HAE – Free Report) in the 4th quarter, Holdings ...

Haemonetics Corporation’s HAE impressive Hospital business recovery is poised to drive growth in the upcoming quarters. The robust uptake of the NexSys PCS system bodes well for its long-term growth.

Haemonetics Corporation (NYSE:HAE), a global healthcare company with a market capitalization of $3.48 billion, has seen its stock price touch a 52-week low, reaching $69.2.

Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 46th Annual Institutional Investors ...

Prior to Medtronic, he held roles of increasing responsibility at Covidien plc (acquired by Medtronic) and DePuy Orthapaedics, Inc. (a Johnson & Johnson company). Galvin joined Haemonetics in 2022 ...

Haemonetics (NYSE:HAE – Get Free Report) had its target price cut by stock analysts at Needham & Company LLC from $108.00 to ...

Needham analyst Michael Matson maintained a Buy rating on Haemonetics (HAE – Research Report) today and set a price target of $104.00. The ...

BOSTON, Feb. 24, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James ...

Haemonetics Corporation’s HAE impressive Hospital business recovery is poised to drive growth in the upcoming quarters. The robust uptake of the NexSys PCS system bodes well for its long-term ...

BOSTON, March 3, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes ...